For immunochemical detection of VMAT2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VMAT2 (C-Term) Polyclonal Antibody

Item No. 29300

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Immunogen
Peptide from the intracellular C-terminal region of human VMAT2 conjugated to KLH
MW
~57 kDa
Formulation (Request formulation change)
100 µl of affinity-purified pooled sheep polyclonal antibody
Storage Buffer
10 mM HEPES, pH 7.5, with 150 mM sodium chloride, 100 µg/ml BSA, and 50% glycerol
Host
Sheep
Applications
WB
Species Reactivity
(+) Human(+) Rat
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    100 µl

    $508

    Add
    Product Description

    Vesicular monoamine transporter 2 (VMAT2) is a member of the SLC18 family of transporters that is encoded by SLC18A2 in humans.1 VMAT2 is expressed in monoaminergic neurons of the central and peripheral nervous systems and localizes to synaptic vesicles where it transports cytosolic dopamine (DA), serotonin (5-HT), norepinephrine (NE), and histamine into synaptic vesicles, regulating cytoplasmic levels and exocytosis of monoamine neurotransmitters. It consists of 12 transmembrane helices, which contain a luminal loop subject to N-glycosylation, as well as cytoplasmic N- and C-terminal domains that regulate monoamine transport and VMAT2 localization, respectively.2 Homozygous knockout of Slc18a2 completely eliminates brain DA, 5-HT, and NE and induces postnatal lethality in mice.3 Slc18a2+/- mice exhibit increased apomorphine-, cocaine-, amphetamine-, or ethanol-induced horizontal locomotor activity compared to wild-type mice. Slc18a2 overexpression decreases immobility time in the forced swim test and marble burying in mice.4 Slc18a2 overexpression also reduces the loss of dopaminergic neurons in a mouse model of Parkinson's disease induced by MPTP. SNPs in SLC18A2 have been found in individuals with bipolar disorder, schizophrenia, drug addiction, and Parkinson's disease.1 Cayman's VMAT2 (C-Term) Polyclonal Antibody can be used for Western blot (WB) applications. The antibody recognizes VMAT2 at approximately 57 kDa from human and rat samples.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Eiden, L.E., and Weihe, E. VMAT2: A dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann. N. Y. Acad. Sci. 1216, 86-98 (2011).

    2. Yaffe, D., Radestock, S., Shuster, Y., et al. Identification of molecular hinge points mediating alternating access in the vesicular monoamine transporter VMAT2. Proc. Natl. Acad. Sci. USA 110(15), E1332-E1341 (2013).

    3. Wang, Y.M., Gainetdinov, R.R., Fumagalli, F., et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19(6), 1285-1296 (1997).

    4. Lohr, K.M., Bernstein, A.I., Stout, K.A., et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 111(27), 9977-9982 (2014).